Could the properties of IL-27 make it an ideal adjuvant for anticancer immunotherapy?
We have recently been the first to demonstrate that interleukin (IL)-27 protects against the emergence and progression of autochthonous tumors. Accumulating evidence suggests that IL-27 might be uniquely well positioned to amplify beneficial TH1 anticancer immune responses while suppressing the unwanted accumulation of regulatory T cells.
|Authors||Swarbrick, A.; Junankar, S. R.; Batten, M.;|
|Published Date||2013-08-01 00:00:00|